The clinical background section nobody reads until rejection

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

The clinical background section is not administrative filler. It is the interpretive framework for everything that follows. When a Notified Body assessor or competent authority reviewer opens your CER, they make critical decisions in the first fifteen pages. They decide whether your scope is defensible, whether your equivalence pathway is credible, and whether your safety claims can be evaluated at all.

If the background section is vague, incomplete, or inconsistent, the rest of the report becomes unevaluable. The literature review might be thorough. The PMCF plan might be well-designed. But without a solid technical and clinical foundation, the assessor cannot verify that your evidence actually addresses the right questions.

I see this pattern repeatedly in pre-submission reviews. Teams focus on data collection and bibliographic searches. They assume the background section is straightforward. Then they receive deficiency letters pointing to fundamental gaps in device description, intended purpose, or claims characterization.

Why the background section determines evaluability

The clinical background section does not just describe your device. It establishes the clinical questions your evaluation must answer. It defines the boundaries of your claims. It sets the standard against which safety and performance will be judged.

Under MDR Article 61 and Annex XIV Part A, the clinical evaluation must demonstrate compliance with General Safety and Performance Requirements (GSPRs) through clinical evidence. But you cannot demonstrate compliance if you have not clearly specified what you are claiming, for whom, under what conditions, and against what benchmark.

The assessor needs to understand your device at three levels: technical, biological, and clinical. Technical means the engineering specifications, materials, and mechanism of action. Biological means how the device interacts with tissue and physiology. Clinical means how it is used in practice, by whom, and for what patient benefit.

When any of these layers is underspecified, the entire evaluation becomes ambiguous. The assessor cannot judge whether your clinical data is relevant. They cannot verify whether your equivalence claim is valid. They cannot assess whether your risk-benefit profile is acceptable.

What the background section must contain

MDCG 2020-5 and Annex XIV outline the structural requirements. But beyond structure, the content must be precise, internally consistent, and connected to the evaluation strategy.

First, the device description must be complete enough that an independent reviewer can reconstruct your classification, your intended purpose, and your claims. This means technical specifications, materials, design features, accessories, variants, and any software or algorithm involved.

But it also means explaining how the device works. Not marketing language. Actual mechanism of action. If it is a cardiovascular stent, describe how radial force is generated, how the platform promotes endothelialization, and how drug elution is controlled. If it is a surgical mesh, explain the polymer structure, the degradation profile, and the mechanical integration with tissue.

Second, the intended purpose and indications must be stated exactly as they appear in the IFU, labeling, and regulatory submission. Any discrepancy between the CER and the technical documentation creates an immediate red flag. The assessor will stop and ask whether the clinical evidence actually covers the marketed claims.

Many teams write intended purpose statements that are too broad or too vague. “For use in surgical procedures” does not specify the clinical context. “To support soft tissue” does not define the anatomical site, the patient population, or the expected duration of support. These ambiguities cascade through the entire report.

Third, claims characterization is critical. You must distinguish between explicit claims (stated in labeling), implicit claims (reasonably inferred from marketing or instructions), and contraindications or limitations. Each claim must be linked to a corresponding clinical question and evidence requirement.

If you claim reduced infection risk, you must demonstrate it. If you claim comparable performance to a predicate, you must define what “comparable” means and what endpoints matter. If you claim suitability for elderly patients, you must address age-related physiology and comorbidities.

The device in its clinical context

The assessor does not evaluate your device in isolation. They evaluate it against the current standard of care, against available alternatives, and against the clinical needs of the target population.

This is where many background sections fail. They describe the device but not the clinical problem it addresses. They list indications but not the patient journey. They state claims but not the context in which those claims matter.

A complete background section situates the device within the treatment pathway. Who are the patients? What is their condition? What are the existing treatment options? What are the limitations of those options? Where does your device fit?

This context is not optional. It directly shapes the state of the art assessment. It determines what endpoints are clinically meaningful. It informs the benefit-risk evaluation. It explains why certain design choices were made and what trade-offs are acceptable.

For example, if your device is a spinal implant for degenerative disc disease, the background section must address the natural history of the condition, the progression of symptoms, the conservative management options, and the surgical alternatives. It must explain why fusion or arthroplasty is indicated, what outcomes matter to patients, and what complications are known.

Without this context, the clinical evidence becomes a disconnected collection of data points. The assessor cannot interpret whether a 10% improvement in pain scores is clinically significant. They cannot judge whether a 2% complication rate is acceptable. They cannot assess whether your device offers a favorable benefit-risk balance.

Consistency across the technical documentation

The background section must align with every other part of your technical documentation. The device description must match the design dossier. The intended purpose must match the IFU. The claims must match the risk management file and the verification and validation reports.

Inconsistencies are immediate red flags. If the CER describes a coating that is not mentioned in the design file, the assessor will question the accuracy of both documents. If the intended purpose in the CER is broader than in the labeling, they will assume you are planning off-label promotion. If the claims in the CER differ from the claims in the preclinical testing reports, they will doubt the validity of your clinical evaluation.

I have seen submissions where the CER described a single-use device, but the IFU included reprocessing instructions. I have seen reports where the intended purpose mentioned pediatric use, but the risk analysis excluded pediatric hazards. These discrepancies do not just trigger deficiencies. They undermine credibility.

The clinical background section is not written in isolation. It is written in coordination with the technical documentation team, the regulatory affairs lead, and the quality management system. Every statement must be traceable to a source document. Every claim must be reflected in the design inputs and verification protocols.

How the background section enables equivalence or clinical investigation decisions

The background section determines whether equivalence is even an option. Under MDCG 2020-5, equivalence requires demonstration of technical, biological, and clinical similarity. You cannot demonstrate similarity if you have not characterized your device at all three levels.

Many equivalence claims fail because the background section did not establish the necessary technical detail. The manufacturer states that both devices are made of stainless steel, but does not specify the alloy grade, the surface finish, or the mechanical properties. The assessor cannot verify similarity. The equivalence pathway collapses.

Similarly, the background section determines whether a clinical investigation is needed. If your device has novel features, a new mechanism of action, or claims that cannot be supported by existing data, the background section must make that clear. Trying to avoid a clinical investigation by downplaying novelty or by overstating equivalence is a strategic mistake. The assessor will see through it.

The background section should enable an honest assessment of the evidence gap. What do we know? What do we need to know? What can be addressed through literature, PMCF, or existing data? What requires a prospective controlled study?

A well-constructed background section makes this assessment straightforward. A poorly constructed one forces the assessor to guess, and when assessors guess, they default to the most conservative interpretation.

Practical structure and level of detail

The background section typically spans ten to twenty pages, depending on device complexity. It should include numbered subsections: device description, intended purpose and indications, claims, clinical context, and current state of the art.

Each subsection should be detailed enough to stand alone. An independent reviewer should be able to read the device description and understand what the device is, how it works, and what makes it distinct. They should be able to read the intended purpose and know exactly what clinical situations the device addresses. They should be able to read the claims and identify what must be proven.

Figures, tables, and diagrams are valuable. A labeled diagram of the device with callouts for key features is more useful than two paragraphs of text. A table listing all device variants with their specifications is clearer than a prose description. A flowchart showing the patient pathway and where the device is used provides immediate context.

But the text must still be precise. Do not rely on figures alone. Every critical statement must be in writing. Every claim must be explicit. Every specification must be traceable.

What happens when the background section is weak

A weak background section creates a cascade of problems. The assessor cannot verify your scope. They cannot validate your equivalence claim. They cannot judge whether your clinical data is relevant. They issue deficiencies, and those deficiencies often require you to go back and rewrite not just the background section, but the entire evaluation strategy.

I have seen teams spend four months responding to a deficiency letter because the initial device description was too vague. The assessor questioned whether the literature review covered the actual device or a different design. The team had to redo the literature search, reassess the equivalence claim, and rewrite the appraisal. All because the background section did not clearly define the technical specifications upfront.

Conversely, a strong background section prevents deficiencies. It demonstrates that you understand your device, your claims, and your evidence obligations. It shows the assessor that the evaluation is grounded in reality, not in wishful thinking. It makes the review process smoother and faster.

The background section is not the most intellectually challenging part of the CER. But it is the most consequential. It determines whether the rest of the report is even evaluable. It deserves the same rigor and attention as the clinical data appraisal.

If you find yourself cutting corners on the background section to get to the “real” clinical evidence faster, you are setting yourself up for rejection. The assessor will not even reach your literature review. They will stop at page twelve and send you back to the beginning.

The clinical background section is the foundation. Build it carefully, build it completely, and build it with the understanding that everything else depends on it.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.